vs
Side-by-side financial comparison of Baozun Inc. (BZUN) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Baozun Inc. is the larger business by last-quarter revenue ($84.2M vs $60.1M, roughly 1.4× RHYTHM PHARMACEUTICALS, INC.). Baozun Inc. runs the higher net margin — -2.0% vs -92.6%, a 90.6% gap on every dollar of revenue.
Baozun Inc is a leading digital commerce service provider focused on the Chinese market. It delivers full-stack e-commerce solutions including official store operation, digital marketing, logistics and fulfillment, customer support, and technical infrastructure services for global and local consumer brands across fashion, beauty, FMCG, consumer electronics, and other core retail segments.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
BZUN vs RYTM — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $84.2M | $60.1M |
| Net Profit | $-1.7M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | -1.7% | -87.1% |
| Net Margin | -2.0% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | $84.2M | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | $-1.7M | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | — | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | -1.7% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | -2.0% | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | — | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.9M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.7M | $122.9M |
| Total Assets | $25.9M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | $6.9M | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | $10.7M | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | $25.9M | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | — | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
